{
  "main_header": {
    "sid": 10039708,
    "name": "Medistep Health.",
    "stock_name": "Medistep Health.",
    "full_name": "Medistep Healthcare Ltd",
    "name_url": "stocks-analysis/medistep-health",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "25.00",
    "chg": -0.05,
    "chgp": "-0.2%",
    "dir": -1,
    "prev_price": "25.05",
    "mcapval": "36.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "MEDISTEP",
    "ind_name": "Diversified consumer products",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0UOY01019",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 12000,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/medistep-health-10039708-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Medistep Health. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medistep-health-overvalued-or-undervalued-3700445",
        "imagepath": "",
        "date": "2025-11-14 08:14:03",
        "description": "As of 13 November 2025, the valuation grade for Medistep Health. has moved from does not qualify to very attractive. This indicates a significant improvement in its valuation outlook. The company is currently assessed as undervalued, supported by a PE ratio of 9.37, an EV to EBIT ratio of 6.86, and a robust ROCE of 34.41%. \n\nIn comparison to its peers, Medistep Health. stands out with a much lower PE ratio than Sun Pharma (36.15) and Divi's Lab (70.4), both of which are categorized as expensive. Additionally, its EV to EBITDA ratio of 6.82 is significantly more favorable than the industry averages, reinforcing its attractive valuation. While Medistep Health. has shown a strong weekly return of 21.88% compared to the Sensex's 1.45%, its longer-term performance metrics remain to be seen...."
      },
      {
        "title": "How has been the historical performance of Medistep Health.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-medistep-health-3695934",
        "imagepath": "",
        "date": "2025-11-13 00:46:00",
        "description": "Answer:\nThe historical performance of Medistep Health shows significant growth over the past three years, particularly in net sales and profitability.\n\nBreakdown:\nMedistep Health's net sales increased from 7.46 Cr in Mar'23 to 31.62 Cr in Mar'24, and further to 49.65 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, rising from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25. The total expenditure also rose significantly from 6.87 Cr in Mar'23 to 44.06 Cr in Mar'25, reflecting the company's expansion efforts. Operating profit (PBDIT) improved from 0.59 Cr in Mar'23 to 5.59 Cr in Mar'25, while profit before tax rose from 0.55 Cr to 5.54 Cr in the same period. Profit after tax followed suit, increasing from 0.41 Cr in Mar'23 to 4.14 Cr in Mar'25. The company's equity capital grew from 1.07 Cr in Mar'23 to 10.47 Cr in Mar'25, and total liabilities increased from 14.95 Cr to 2..."
      }
    ],
    "total": 2,
    "sid": "10039708",
    "stock_news_url": "https://www.marketsmojo.com/news/medistep-healthcare-10039708"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Medistep Health. overvalued or undervalued?

2025-11-14 08:14:03

As of 13 November 2025, the valuation grade for Medistep Health. has moved from does not qualify to very attractive. This indicates a significant improvement in its valuation outlook. The company is currently assessed as undervalued, supported by a PE ratio of 9.37, an EV to EBIT ratio of 6.86, and a robust ROCE of 34.41%. In comparison to its peers, Medistep Health. stands out with a much lower PE ratio than Sun Pharma (36.15) and Divi's Lab (70.4), both of which are categorized as expensive. Additionally, its EV to EBITDA ratio of 6.82 is significantly more favorable than the industry averages, reinforcing its attractive valuation. While Medistep Health. has shown a strong weekly return of 21.88% compared to the Sensex's 1.45%, its longer-term performance metrics remain to be seen....

Read More

How has been the historical performance of Medistep Health.?

2025-11-13 00:46:00

Answer: The historical performance of Medistep Health shows significant growth over the past three years, particularly in net sales and profitability. Breakdown: Medistep Health's net sales increased from 7.46 Cr in Mar'23 to 31.62 Cr in Mar'24, and further to 49.65 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, rising from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25. The total expenditure also rose significantly from 6.87 Cr in Mar'23 to 44.06 Cr in Mar'25, reflecting the company's expansion efforts. Operating profit (PBDIT) improved from 0.59 Cr in Mar'23 to 5.59 Cr in Mar'25, while profit before tax rose from 0.55 Cr to 5.54 Cr in the same period. Profit after tax followed suit, increasing from 0.41 Cr in Mar'23 to 4.14 Cr in Mar'25. The company's equity capital grew from 1.07 Cr in Mar'23 to 10.47 Cr in Mar'25, and total liabilities increased from 14.95 Cr to 2...

Read More

View All News